Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer

Plain-language summary

This study aims to identify risk factors for cancer recurring in the brain (brain recurrence) in patients with HER2-positive localized breast cancer. It enrolls female patients aged 18 and over with histologically proven HER2-positive breast cancer who are scheduled for neoadjuvant chemotherapy and undergo a pre-treatment biopsy. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Center Eugene Marquis

Intervention

Pre-treatment biopsy

Start date

6/6/2024

Estimated completion

6/6/2031

Countries

France

Related genes

Locations

• Rennes, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age ≥ 18 years old
* be a female patient
* Patients with histologically proven HER2-positive invasive breast cancer (IHC 3+ or 2+ with positive SISH),
* Neoadjuvant chemotherapy and intra-tumour clips indicated at the multidisciplinary consultation meeting (RCP).
* Signed Informed Consent Form

Exclusion Criteria:

* pregnant or breast-feeding women
* Have had a haematoma requiring level II analgesics at the time of the diagnostic biopsy.
* Known coagulation disorders
* Individual deprived of liberty or placed under the authority of a tutor, or a currator
* Not be affiliated to a social security regimen